Fig. S1. FeCl2 treatment inhibits proteasomes. (A) Immunoblotting of cell lysates with anti-ubiquitin antibody (Mab 1510, Chemicon). FeCl2-treated samples displayed more high-molecular-weight (HMW) proteins with ubiquitin (ubiq) immunoreactivities. The arrow indicates ubiquitin monomer. (B) Quantitative analysis of ubiquitin-immunoreactive proteins of molecular weight > 75 kDa. Student?s t-test, N = 6, *P < 0.05. (C) Proteasomal activity assay using fluorogenic peptides as substrate. Chymotrypsine-like activity was lower in Fe(+) than Fe(?) controls, and higher in Syn(+) than Syn(?) cells without the FeCl2 treatment, N = 6, *P < 0.05. The specificity of activity assay was verified by analysis of lysates in the presence of the proteasome inhibitor, epoxomicin.

EJN_5736_sm_FigS1.jpg119KSupporting info item

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.